title: Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.
abstract: BACKGROUND
  To date, there are no data on long-term use of enteric-coated mycophenolate sodium (EC-MPS; myfortic) from time of renal transplantation. We report the first long-term safety and efficacy data on EC-MPS when administered for up to 3 years post transplant.
  
  
  METHODS
  De novo renal transplant recipients completing 1 year of treatment in a multicenter, randomized, double-blind trial of EC-MPS versus mycophenolate mofetil (MMF) were invited to take part in an open-label extension during which all patients received EC-MPS 720 mg b.i.d. Results from the period 12 - 36 months post transplant were compared to comparable data from MMF-treated patients taking part in two studies of everolimus versus MMF (RAD 201 and RAD 251).
  
  
  RESULTS
  Of 367 patients completing the blinded core study, 247(62%) entered the open-label extension phase. During the first 24 months of the extension, the incidence, type and severity of adverse events were comparable between the newly-exposed and long-term EC-MPS patients. There were 2 deaths in the newly-exposed group and 4 among long-term EC-MPS patients, with 1 and 2 graft losses, respectively. Six patients (5%) in the newly-exposed group and 4 (3%) in the long-term EC-MPS group experienced biopsy-proven acute rejection. Cross-study comparisons indicated that the tolerability profile of EC-MPS was similar to MMF, including the incidence of adverse events, infections and malignancies, as was the incidence of efficacy events.
  
  
  CONCLUSIONS
  These results demonstrate that EC-MPS with cyclosporine and steroids provides good long-term efficacy and tolerability, and confirm the safety of converting renal transplant patients from MMF to EC-MPS.
authors.affiliation: Renal Unit, Careggi University Hospital, Florence, Italy. salvadorim@ao-careggi.toscana.it
authors.forename: M
authors.initials: M
authors.lastname: Salvadori
authors.forename: H
authors.initials: H
authors.lastname: Holzer
authors.forename: G
authors.initials: G
authors.lastname: Civati
authors.forename: H
authors.initials: H
authors.lastname: Sollinger
authors.forename: B
authors.initials: B
authors.lastname: Lien
authors.forename: S
authors.initials: S
authors.lastname: Tomlanovich
authors.forename: E
authors.initials: E
authors.lastname: Bertoni
authors.forename: Y
authors.initials: Y
authors.lastname: Seifu
authors.forename: A C
authors.initials: AC
authors.lastname: Marrast
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D012449:Safety; D013608:Tablets, Enteric-Coated; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D013608:Tablets, Enteric-Coated; D009173:Mycophenolic Acid